Profiles

Keywords
Last Name
Institution

Connection

Search Results to Donald M. Jensen

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following items that are connected to Jensen, Donald

Item TypeName
Concept Recombinant Proteins
Academic Article Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin.
Academic Article Induction of IL-1Ra in resistant and responsive hepatitis C patients following treatment with IFN-con1.
Academic Article A pilot study of the combination of cyclosporin A and interferon alfacon-1 for the treatment of hepatitis C in previous nonresponder patients.
Academic Article Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C.
Academic Article Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin.
Academic Article Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.
Academic Article Ribavirin in the treatment of chronic hepatitis C.
Academic Article Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin.
Academic Article Marked flare in hepatic aminotransferases during treatment with pegylated interferon for chronic hepatitis C, genotype 2: a case report.
Academic Article Sustained viral response after interferon-based therapy in chronic hepatitis C: more evidence to support a life-long cure.
Academic Article Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial.
Academic Article Treatment duration for genotypes 2 and 3: still confusing after all these years.
Academic Article A new era of hepatitis C therapy begins.
Academic Article Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future.
Academic Article Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients.
Academic Article Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies.
Academic Article Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment.
Academic Article Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.
Academic Article Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C.
Academic Article Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.

Search Criteria
  • Recombinant Proteins